UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 23 von 343
Datensatz exportieren als...
BibTeX
Cutaneous B‐cell lymphomas: 2015 update on diagnosis, risk‐stratification, and management
American journal of hematology, 2015-01, Vol.90 (1), p.73-76
Wilcox, Ryan A.
2015
Details
Autor(en) / Beteiligte
Wilcox, Ryan A.
Titel
Cutaneous B‐cell lymphomas: 2015 update on diagnosis, risk‐stratification, and management
Ist Teil von
American journal of hematology, 2015-01, Vol.90 (1), p.73-76
Ort / Verlag
United States: Wiley Subscription Services, Inc
Erscheinungsjahr
2015
Link zum Volltext
Quelle
Wiley Online Library - AutoHoldings Journals
Beschreibungen/Notizen
Disease overview: Approximately one‐fourth of cutaneous lymphomas are B‐cell derived and are generally classified into three distinct subgroups: primary cutaneous follicle center lymphoma (PCFCL), primary cutaneous marginal zone lymphoma (PCMZL), and primary cutaneous diffuse large B‐cell lymphoma, leg type (PCDLBCL, LT). Diagnosis: Diagnosis and disease classification is based on histologic review and immunohistochemical staining of an appropriate skin biopsy. Pathologic review and an appropriate staging evaluation are necessary to distinguish primary cutaneous B‐cell lymphomas from systemic B‐cell lymphomas with secondary skin involvement. Risk‐stratification: Disease histology remains the most important prognostic determinant. Both PCFCL and PCMZL are indolent lymphomas that infrequently disseminate to extracutaneous sites and are associated with 5‐year survival rates that exceed 95%. In contrast, PCDLBCL, LT is an aggressive lymphoma with an inferior prognosis. Risk‐adapted therapy: PCFCL and PCMZL patients with solitary or relatively few skin lesions may be affectively managed with local radiation therapy. While single‐agent rituximab may be employed for patients with more widespread skin involvement, multiagent chemotherapy is rarely appropriate. In contrast, management of patients with PCDLBCL, LT is comparable to the management of patients with systemic DLBCL. Am. J. Hematol. 90:74–76, 2015. © 2014 Wiley Periodicals, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0361-8609
eISSN: 1096-8652
DOI: 10.1002/ajh.23863
Titel-ID: cdi_proquest_miscellaneous_1640331235
Format
–
Schlagworte
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
,
Disease-Free Survival
,
Humans
,
Lymphoma, B-Cell, Marginal Zone - diagnosis
,
Lymphoma, B-Cell, Marginal Zone - mortality
,
Lymphoma, B-Cell, Marginal Zone - therapy
,
Lymphoma, Follicular - diagnosis
,
Lymphoma, Follicular - mortality
,
Lymphoma, Follicular - therapy
,
Lymphoma, Large B-Cell, Diffuse - diagnosis
,
Lymphoma, Large B-Cell, Diffuse - mortality
,
Lymphoma, Large B-Cell, Diffuse - therapy
,
Practice Guidelines as Topic
,
Prognosis
,
Radiotherapy
,
Risk
,
Skin Neoplasms - diagnosis
,
Skin Neoplasms - drug therapy
,
Skin Neoplasms - mortality
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX